Author: Ivashchenko, Andrey A; Dmitriev, Kirill A; Vostokova, Natalia V; Azarova, Valeria N; Blinow, Andrew A; Egorova, Alina N; Gordeev, Ivan G; Ilin, Alexey P; Karapetian, Ruben N; Kravchenko, Dmitry V; Lomakin, Nikita V; Merkulova, Elena A; Papazova, Natalia A; Pavlikova, Elena P; Savchuk, Nikolay P; Simakina, Elena N; Sitdekov, Tagir A; Smolyarchuk, Elena A; Tikhomolova, Elena G; Yakubova, Elena V; Ivachtchenko, Alexandre V
Title: AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial Cord-id: nq3aacnr Document date: 2020_8_9
ID: nq3aacnr
Snippet: In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.
Document: In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.
Search related documents:
Co phrase search for related documents- loading dose and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date